CI Investments Inc. decreased its position in Bristol-Myers Squibb Co (NYSE:BMY) by 13.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,075,680 shares of the biopharmaceutical company’s stock after selling 165,400 shares during the quarter. CI Investments Inc. owned 0.07% of Bristol-Myers Squibb worth $68,564,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Xact Kapitalforvaltning AB grew its holdings in shares of Bristol-Myers Squibb by 3.4% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 286,425 shares of the biopharmaceutical company’s stock valued at $15,960,000 after acquiring an additional 9,310 shares in the last quarter. Boltwood Capital Management grew its holdings in Bristol-Myers Squibb by 1.7% during the second quarter. Boltwood Capital Management now owns 18,205 shares of the biopharmaceutical company’s stock worth $1,014,000 after purchasing an additional 300 shares during the period. Trust Co grew its holdings in Bristol-Myers Squibb by 1.8% during the first quarter. Trust Co now owns 54,428 shares of the biopharmaceutical company’s stock worth $2,960,000 after purchasing an additional 969 shares during the period. Carlton Hofferkamp & Jenks Wealth Management LLC grew its holdings in Bristol-Myers Squibb by 12.7% during the second quarter. Carlton Hofferkamp & Jenks Wealth Management LLC now owns 8,900 shares of the biopharmaceutical company’s stock worth $495,000 after purchasing an additional 1,000 shares during the period. Finally, First Command Bank grew its holdings in Bristol-Myers Squibb by 3.1% during the second quarter. First Command Bank now owns 3,302 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 100 shares during the period. 69.70% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Bristol-Myers Squibb Co (BMY) traded down $2.52 during mid-day trading on Monday, reaching $60.96. 23,180,000 shares of the company’s stock traded hands, compared to its average volume of 6,640,000. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. The firm has a market capitalization of $99,770.00, a P/E ratio of 24.00, a PEG ratio of 2.19 and a beta of 1.08. Bristol-Myers Squibb Co has a 1 year low of $50.36 and a 1 year high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The firm had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same period last year, the business posted $0.63 earnings per share. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. research analysts forecast that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Friday, January 5th were given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.62%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date was Thursday, January 4th. Bristol-Myers Squibb’s payout ratio is presently 62.99%.
In other news, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the sale, the executive vice president now directly owns 9,251 shares in the company, valued at $585,033.24. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by insiders.
BMY has been the subject of a number of research analyst reports. Credit Suisse Group reiterated a “hold” rating and set a $61.00 price target (up previously from $58.00) on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Piper Jaffray Companies reiterated a “hold” rating and set a $60.00 price target on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Leerink Swann lifted their price target on Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a report on Monday, October 23rd. Zacks Investment Research upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Friday, January 19th. Finally, BMO Capital Markets set a $49.00 price target on Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Monday, December 11th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $65.38.
TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/05/ci-investments-inc-has-68-56-million-stake-in-bristol-myers-squibb-co-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.